13-20　ⓔ文献

1. Takahashi H, Yamamoto M, et al: The birthday of a new syndrome: IgG4–related diseases constitute a clinical entity. Autoimmun Rev, 2010; 9: 591–594.

2. Yamamoto M,Takahashi H, et al: Mechanisms and assessment of IgG4–related disease: lessons for the rheumatologist. Nat Rev Rheumatol, 2014; 10: 148–159.

3. Tanaka A, Moriyama M, et al: Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease. Arthritis Rheum, 2012; 64: 254–263.

4. Watanabe T, Yamashita K, et al: Involvement of activation of Toll–like receptors and nucleotide–binding oligomerization domain–like receptors in enhanced IgG4 responses in autoimmune pancreatitis. Arthritis Rheum, 2012; 64: 914–924.

5. Takano K, Yajima R, et al: A study of infra–orbital nerve swelling associated with immunoglobulin G4 Mikulicz's disease. Mod Rheumatol, 2014; 24: 798–801.

6. Inoue D, Zen Y, et al: CT findings of thoracic paravertebral lesions in IgG4–related disease. Am J Roentgenol, 2019; 213: W99–W104.

7. 梅原久範，岡崎和一，他：2020年改訂　IgG4関連疾患包括診断基準．日本内科学会雑誌，2021; 110: 962–969.

8. Wallece ZS, Naden RP, et al: The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4–related disease. Ann Rheum Dis, 2019; 79: 77–87.

9. Yamamoto M, Takahashi H, et al: Risk of malignancies in IgG4–related disease. Mod Rheumatol, 2012; 22: 414–418.

10. Khosroshahi A,Wallace ZS, et al: International consensus guidance statement on the management and treatment of IgG4–related disease. Arthritis Rheum, 2015; 67: 1688–1699.

11. 高橋裕樹：IgG4関連疾患．GUIDELINE膠原病・リウマチ―治療ガイドラインをどう読むか―(小池隆夫，住田孝幸編)，診断と治療社，2010; 43–49.

12. Masamune A, Nishimori I, et al: Randomised controlled trial of long–term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut, 2017; 66: 487–494.

13. Masaki Y, Matsui S, et al: A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4–related disease. Mod Rheumatol, 2017; 27: 849–854.